000 03816nam a22004335i 4500
999 _c10322
_d10322
001 10322
003 DE-He213
005 20210608040358.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 180119s2018 gw | s |||| 0|eng d
020 _a9783319701974
024 7 _a10.1007/978-3-319-70197-4
_2doi
040 _aES-MaUEC
_bspa
_dES-MaUEC
050 4 _aRC280 .B74
_b2018 EB
245 0 0 _aOptimizing Breast Cancer Management
_cedited by William J. Gradishar.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2018.
300 _a1 recurso en línea (V, 189 páginas 11 ilustraciones a color)
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aCancer Treatment and Research,
_x0927-3042 ;
_v173
490 0 _aMedicine (Springer-11650)
505 0 _aStrategies to maintain fertility in young breast cancer patients -- Sexual dysfuncton in breast cancer survivors -- The breast cancer screening conundrum -- New Imaging modalities in breast cancer -- Is DCIS over treated -- “Personalizing” Breast Radiation -- Management of the axilla in early stage breast cancer -- Management of the breast in denovo MBC -- Identification of genetic lesions in patients with strong family history and no BRCA Mutation -- Managing “testing expectations” in breast cancer survivors -- The role of bone strengthening agents in early and advanced disease -- Overcoming endocrine resistance -- Optimal Adjuvant endocrine therapy -- Choosing wisely in HER2 positive metastatic breast cancer -- Should early stage, triple negative breast cancer be treated with preoperative systemic therapy?
520 3 _aThis book presents expert opinions on a variety of key topics related to the management of breast cancer, with a focus on the implications of recent advances and research findings for clinical practice. It also explores the controversy regarding mammography screening and reviews the contribution of new imaging modalities. Considerable attention is paid to developments in surgical procedures, including the potential for the safe and effective use of sentinel lymph node dissection alone—even in patients with positive nodes—and to the advantages and contraindications of new radiotherapy techniques. Genetic aspects are discussed in detail, including an assessment of the role of genetic testing and the potential impact of genetic signatures on breast cancer management. New systemic strategies, such as anti-HER2 therapy, endocrine agents, and agents to reverse endocrine resistance, are considered, and the optimal use of chemotherapy for early-stage and advanced-stage disease is addressed. In closing, the book shares important new insights into lifestyle risk factors, risk reduction strategies, and survivor issues, including sexual dysfunction and fertility maintenance.
988 _aEBSPRINGER_2018
650 7 _aOncología
_9139207
_2embne
650 7 _aGinecología
_2embne
_9138562
650 7 _aMamas
_xCáncer
_2embne
_9182522
700 1 _aGradishar, William J.
_eeditor literario
_0http://id.loc.gov/authorities/names/n00121853
_0http://viaf.org/viaf/32253484
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_0http://viaf.org/viaf/148105729
_9106996
776 0 8 _iEdición impresa:
_z9783319701950
776 0 8 _iEdición impresa:
_z9783319701967
776 0 8 _iEdición impresa:
_z9783319889016
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-70197-4
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0